Significant advances, particularly in immunotherapy, have been made in the treatment of cancers, a leading cause of death in humans [1][2] [3] [4] [5] [6] . Immune-checkpoint inhibitors, including anti-PD1 and anti-CTLA4, have shown clinical efficacy for some tumors, but not for many others, including CRCs 5,7-9 . Although mechanisms for resistance and/or insensitivity to current checkpoint inhibitors have been described 10 , there are more mechanisms for tumor immune modulation yet to be discovered.
, the conventional wisdom is that DKK2 inactivation might increase Wnt activity and lead to or accelerate cancer formation. However, our findings in this study were contrary to what was expected: DKK2, which shows upregulated expression in human CRCs and cells with APC-loss mutations, promoted tumor progression by suppressing the activation of immune effector cells.
RESULTS

Loss of APC drives DKK2 expression
Analysis of the Gaedcke cohort 34 in the Oncomine database (https:// www.oncomine.org) showed that DKK2 expression is significantly upregulated in human CRC samples compared with its expression in non-tumorous colorectal tissues (P < 0.01; Supplementary Fig. 1a) , which is in agreement with a previous finding 35 . Analysis of Cancer Genome Atlas Network data sets 36 further revealed that DKK2 expression in microsatellite-stable (MSS) CRCs, more than 80% of which harbor APC mutations, is significantly higher than that in microsatellite-instable CRCs (P < 0.05; Supplementary Fig. 1a ). In mice, the Dkk2 mRNA content in the intestinal polyps of Apc Min/+ mice, a mouse genetic intestinal tumor model 37 , was about four times higher than that in normal intestinal tissue (Supplementary Fig. 1b) . Immunostaining of DKK2 protein and in situ hybridization of Dkk2 mRNA confirmed upregulated DKK2 expression in the polyps ( Supplementary  Fig. 1c,d ). In mouse colon cancer MC38 cells in which Apc was mutated by CRISPR-Cas9, DKK2 expression was markedly upregulated in APC-null cells (Supplementary Fig. 1e ). This upregulation was suppressed by β-catenin small interfering RNAs ( Supplementary  Fig. 1f) , which suggested the involvement of β-catenin in driving DKK2 expression. APC loss also led to upregulation of DKK2 expression in human colon cancer HCT116 cells (Supplementary Fig. 1g ). Therefore, we conclude that APC loss drives DKK2 expression in both mouse and human CRC cells.
DKK2 blockade suppresses APC-loss-induced tumor formation
Analysis of the TCGA CRC data sets showed that high DKK2 expression correlates with poor survival rates ( Supplementary  Fig. 1h ). This suggests that DKK2 may have an important role in CRCs. Concordantly, DKK2 deficiency was associated with significantly reduced intestinal polyp burdens in both male and female Apc Min/+ mice compared with those in wild-type mice ( Fig. 1i ). We then generated a mouse monoclonal antibody to DKK2 (designated as 5F8), and found that it bound to mouse DKK2, but not to DKK1 (Fig. 1d) . The antibody inhibited DKK2-mediated, but not DKK1-mediated, antagonism of Wnt activation (Fig. 1e) . Moreover, 5F8 blocked the binding of DKK2 to LRP5 (Fig. 1f) . Administration of 5F8 significantly extended survival and reduced intestinal polyp burdens (depending on the presence of DKK2) in Apc Min/+ mice compared with mice treated with an isotype control antibody ( Fig. 1g and Supplementary Fig. 2a-c) .
Of note, an antibody to PD-1 showed no significant effect on polyp burden in these mice (data not shown), which is consistent with the reported lack of therapeutic efficacy of PD-1 blockade on human MSS CRCs 5,7-9 . These results together support the conclusion that DKK2 blockade suppresses the formation of intestinal polyps, a form of nonmalignant tumor, caused by APC loss. Thus, rather than impeding it, as one might have predicted on the basis of the known mechanism of action, DKK2 supports tumor progression.
DKK2 blockade modulates tumor immune microenvironment
In experiments with a syngeneic mouse colon cancer model, 5F8 significantly inhibited the growth of subcutaneously grafted MC38 cells in C57BL/6 mice ( Fig. 2a) and extended the survival of tumor-bearing mice (Fig. 2b ) compared with that in mice treated with isotype control antibody (IgG3). As 5F8 did not affect the growth of MC38 cells in culture (Fig. 2c) , the antibody might impede tumor progression by altering the tumor microenvironment. Immunohistological examination of the MC38 tumors revealed that 5F8 had no significant effects on angiogenesis (Fig. 2d) or tumor cell proliferation (Fig. 2e) . However, treatment with 5F8 increased the number of apoptotic cells (Fig. 2f) and GZMB + cells (Fig. 2g) . We also observed increases in apoptosis and GZMB expression in Apc Min/+ Dkk2 −/− polyps compared with that in Apc Min/+ polyps ( Supplementary Fig. 2d ,e) and in 5F8-treated polyps compared with that in IgG3-treated polyps (data not shown). DKK2 blockade did not significantly affect proliferation, infiltration of cytotoxic immune cells, or differentiation in the polyps ( Supplementary Fig. 2f-i) . Because GZMB is largely produced by NK cells and CD8 + T cells and induces tumor cell apoptosis 38 , the above results suggest that DKK2 blockade may modulate the immune microenvironment. In support of this conclusion, when we grafted MC38 cells onto immunodeficient NSG mice, which lack mature leukocytes, and administered 5F8, the antibody did not show any tumor-suppressive effect (Fig. 3a,b) .
DKK2 blockade enhances NK cell and CD8 + T cell activation Consistent with the immunostaining results (Fig. 2g) , flow cytometry analysis of tumor-infiltrating leukocytes showed that 5F8 treatment increased the amount of GZMB in both CD8 + T cells and NK1.1 + T cells (Supplementary Fig. 3a-g ). In contrast, there were no differences between 5F8-treated and isotype-treated samples in terms of the percentages of myeloid cells (Gr1 hi CD11b hi or Gr1 lo CD11b hi ), CD4 + T cells, CD8 + T cells, T reg cells (CD4 + CD25 + Foxp3 + ), and NK1.1 + T cells ( Supplementary Fig. 3b-e) . Analysis of leukocytes in tumor-draining lymph nodes showed that there were no differences among the populations of CD4 + T cells, CD8 + T cells, or NK1.1 + T cells ( Supplementary Fig. 3h,i) , whereas there was a trend for increased amounts of GZMB in CD8 + T cells ( Supplementary  Fig. 3j ) and a substantial increase in GZMB expression in NK1.1 + T cells in 5F8-treated samples compared with that in IgG3-treated samples (Supplementary Fig. 3k ). We also observed increased numbers of GZMB + CD8 + T cells in Peyer's patches and draining lymph Figure 2 DKK2 blockade impedes tumor progression in the MC38 syngeneic tumor model. (a,b) C57BL/6 mice inoculated with MC38 cells were treated with 5F8 (10 mg/kg i.p. every 3 d) starting at day 14 after inoculation. Tumors from some of the mice were collected at day 22 and weighed (P = 0.002 and P < 0.001 for tumor growth at days 20 and 22, respectively; two-way ANOVA; two-tailed Student's t-test for tumor weight; n = 5). The rest of the mice were used for evaluation of survival (P = 0.004 for 5F8-treated versus IgG-treated; two-sided log-rank Mantel-Cox test; n = 10). (c) The 5F8 antibody did not affect MC38 cell growth in culture (n = 4). (d-g) Effects of 5F8 treatment on tumor angiogenesis, tumor cell proliferation and apoptosis, and numbers of GZMB + cells were evaluated by staining of the sections of tumor collected in a for CD31 (d), Ki67 (e), cleaved caspase-3 (f), and GZMB (g). The sections were also counterstained with DAPI. Five independent sections per tumor and five tumors per group were examined (two-sided Student's t-test). Data are presented as mean ± s.e.m., with P values shown in plots where relevant (a,c-g). Individual data points represent individual tumors. All experiments were repeated twice. Scale bars, 100 µm.
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To exclude the effect of tumor size on the flow cytometry results, we treated MC38-tumor-bearing mice with antibodies for only 24 h before analysis. At this time point, there were no obvious differences in tumor size. Although there were still no significant differences in the populations of CD4 + T cells, CD8 + T cells, or NK1.1 + T cells (Fig. 3c,d) , we observed strong increases in GZMB expression in tumor-infiltrating CD8 + T cells and NK1.1 + T cells in 5F8-treated mice compared with that in isotype-treated mice (Fig. 3e,f) . We also observed significant increases in levels of other activation markers of CD8 + T cells and NK cells, including CD69, CD107a, CD314, IFN-γ, and CD25 on CD8 + T cells, and CD69, IFN-γ, NKp46, and CD314 on NK cells (Fig. 3g,h) . We did not observe any significant changes in levels of Ki67, T-bet, Eomes, phospho-mTOR, phospho-S6K, phospho-AKT, KLGR1, CD122, or CD127 in 5F8-treated CD8 + T cells or NK1.1 + cells compared with levels in cells from isotype-treated mice (Supplementary Fig. 4c,d) . Acute 5F8 treatment also considerably increased the number of GZMB + CD8 + T cells in Peyer's patches of Apc Min/+ mice compared with those in IgGtreated mice, without affecting the overall size of the T cell populations (Supplementary Fig. 4e,f) .
To assess the importance of cytotoxic immune effector cells in DKK2-blockade-mediated tumor suppression, we depleted NK cells with anti-NK1.1 and depleted CD8 + T cells with anti-CD8 in the MC38 tumor model (Supplementary Fig. 5a-c) . Depletion of either NK cells or CD8 + T cells largely diminished the tumor-suppressive effect of 5F8, with NK cell depletion perhaps having a stronger effect (Fig. 3i,j) . We also depleted these same cell populations in the Apc Min/+ model. Whereas NK1.1 + T cell depletion did not noticeably alter the effect of 5F8 on polyp formation, CD8 + T cell depletion largely abrogated the effect of 5F8 (Supplementary Fig. 5d ). These results indicate that cytotoxic immune effector cells have important roles in DKK2-blockade-mediated suppression of tumor formation.
DKK2 directly suppresses cytotoxic immune cells
Next we assessed the effect of DKK2 blockade on the cytotoxicity of primary NK cells. Inclusion of 5F8 caused a marked increase in GZMB expression in NK cells (Fig. 4a) and decreased tumor cell viability (Fig. 4b) in cocultures of IL-15-expanded primary mouse NK cells and MC38 cells. By contrast, in cultures of only one or the other cell type, 5F8 treatment showed little effect on GZMB expression in NK cells (Fig. 4c) or on the viability of MC38 cells (Fig. 2c) .
We carried out microarray gene expression analyses, and did not observe significantly altered expression of IL-2, IL-15, MHC-I haplotypes, NKG2D ligands (RAE-1α-ε, MULT-1, and H60a-c), Fas, or TRAILR1/2, all of which are important for NK cell activity, in 5F8-treated MC38 cells or tumors compared with expression in IgG3-treated samples (data not shown). In addition, Dkk2 mRNA a r t i c l e s 2 6 6 VOLUME 24 | NUMBER 3 | MARCH 2018 nature medicine was hardly detectable by RT-PCR in NK cells, whereas it was readily detectable in MC38 cells (Supplementary Fig. 1e ). On the basis of both these results and the aforementioned coculture results, we postulated that tumor-cell-produced DKK2 might act directly on NK cells. Indeed, the addition of recombinant DKK2 protein to primary NK cells cultured with IL-15 caused 5F8-reversible reductions in levels of GZMB, CD69, IFN-γ, CD107a, CD314 (Fig. 4d,e) , KLRG1, and CD122 ( Supplementary Fig. 6a ). These inhibitory effects of DKK2 were dose dependent ( Fig. 4f ) and were also observed for NK cells stimulated with IL-12 and IL-18 ( Supplementary Fig. 6b ). DKK2 also had significant effects on tumor-killing ability, as NK cells pretreated with DKK2 had a reduced ability to cause tumor cell apoptosis and death ( Fig. 4g) . Additionally, DKK2 inhibited IL-15-mediated activation of human NK cells and CD8 + T cells isolated from peripheral blood ( Supplementary  Fig. 6c,d ). Furthermore, DKK2 suppressed the response to IL-15 in mouse primary CD8 + T cells isolated from spleen and CD8 + IELs ( Supplementary Fig. 6d ,e). Thus, DKK2 could directly suppress the activation of both human and mouse immune effector cells.
DKK2 inhibits NK cell activation independently of Wnt-bcatenin signaling
Next, we tested whether Wnt-β-catenin signaling is responsible for NK cell regulation by DKK2, as DKK2 can inhibit this pathway. WNT3A induced a strong increase in Wnt reporter gene activity, which could be inhibited by DKK2 (Supplementary Fig. 7a ). WNT3A also induced β-catenin accumulation in primary NK cells ( Supplementary Fig. 7b ). However, WNT3A did not alter GZMB expression in NK cells (Fig. 4h) . Concordantly, the GSK3 inhibitor CHIR99021, which increases β-catenin stability by bypassing Wnt and its receptors and strongly stimulated Wnt reporter gene activity ( Supplementary Fig. 7a ), did not affect primary NK cells (Fig. 4h) .
Therefore, it seems likely that DKK2-mediated inhibition of NK cell activation is independent of Wnt-β-catenin signaling. These results also distinguish the mechanism of action of DKK2 from that described in recent reports indicating involvement of Wnt-β-catenin signaling in the modulation of tumor immune microenvironments 39, 40 .
DKK2 impedes nuclear localization of phosphorylated STAT5
Given that DKK2 suppressed cytotoxic immune cell activation by IL-15, we examined the effects of DKK2 treatment on various signaling events stimulated by IL-15. Although we observed reductions in amounts of GZMB and perforin proteins in DKK2-treated samples, we did not detect any notable changes in the phosphorylation of STAT5, ERK, AKT ( Fig. 5a) , MTOR, S6K, STAT1, or STAT4 ( Supplementary Fig. 8a,b) . DKK2 treatment did not induce any changes in cell size ( Supplementary Fig. 8c ), and it is known that DKK2 does not alter the MTORC1 pathway, which can affect GZMB expression in NK cells 17, 18 . However, RNA-seq analysis of DKK2-treated and mock-treated primary NK cells suggested an alteration in STAT5 signaling after DKK2 treatment ( Supplementary Fig. 8d ,e and Supplementary Table 1) . We thus examined the localization of pSTAT5 a step downstream of STAT5 phosphorylation. Whereas IL-15 induced nuclear localization of pSTAT5 as expected, cytosolic localization of pSTAT5 was readily detected in DKK2-treated cells ( Fig. 5b and Supplementary Fig. 8f ). This result was further confirmed by subcellular fractionation (Supplementary Fig. 8g ). Furthermore, NK cells isolated from 5F8-treated tumors showed reduced cytosolic localization of pSTAT5 compared with that in cells isolated from control IgG-treated tumors ( Fig. 5c and Supplementary Fig. 8h ). pSTAT5 was partially colocalized with early endosome marker EEA1 ( Fig. 5d ), but not with late endosome marker LAMP1 ( were cultured with IL-15 (50 ng/ml) for 24 h. DKK2 protein (400 ng/ml for d and e; varying amounts for f) was then added for another 24 h, after which the samples were analyzed by flow cytometry (P values for DKK2 versus mock; n = 3; two-sided Student's t-test). (g) Primary NK cells were expanded in IL-15 (50 ng/ml) for 24 h and then treated with or without DKK2 (400 ng/ml) or 5F8 (36 µg/ml) for 24 h. The NK cells were then added at a 7:1 ratio to MC38 cells that had been seeded the day before. The number of apoptotic MC38 cells was determined after 6 h, and the number of live MC38 cells was determined after 9 h of coculture (n = 3; one-way ANOVA). (h) Isolated primary mouse NK cells were cultured with IL-15 (50 ng/ml) for 24 h. DKK2 protein (400 ng/ml), WNT3A (100 ng/ml), and GSK3 inhibitor CHIR99021 (CHIR; 1 µM) were then added for another 24 h, after which the samples were analyzed by flow cytometry (n = 3; one-way ANOVA). Data are presented as mean ± s.e.m. (a-e,g,h) with P values shown in plots where relevant (a,b,d,e,g,h), and the experiments were repeated three (a-f) or two (g,h) times; data in f are representative of one of the three repeated experiments.
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DKK2 acts through LRP5, but not LRP6 DKK2 binds to LRP5 and LRP6. Although DKK2 inhibited the activation of primary NK cells that lacked LRP6 ( Supplementary  Fig. 9a ), it did not inhibit LRP5-deficient NK cells (Fig. 6a) . Additionally, DKK2 did not impair pSTAT5 nuclear localization in NK cells that lacked LRP5 (Fig. 6b) . Thus, LRP5, but not LRP6, is required for DKK2's action on NK cells. The fact that LRP5 deficiency did not affect β-catenin accumulation stimulated by WNT3A in NK cells (Supplementary Fig. 7b ) further confirms that the effect of the DKK2-LRP5 axis on NK activation is independent of Wnt-β-catenin signaling. LRP6 instead is required for Wnt-β-catenin signaling in NK cells, as WNT3A did not induce β-catenin accumulation in LRP6-deficient NK cells (Supplementary Fig. 9b ).
We then tested the importance of LRP5 in tumor progression and the antitumor effect of DKK2 blockade by using hematopoieticspecific knockout of LRP5, which we accomplished by adoptive transfer of bone marrow from Lrp5 fl/fl Mx1 Cre mice into lethally irradiated wild-type C57BL/6 mice. The lack of LRP5 in hematopoietic cells impaired MC38 tumor progression (Fig. 6c) . We observed that 5F8 did not affect tumor progression in mice expressing mutant LRP5, whereas its effect was retained in the control mice (Fig. 6c) . Flow cytometry analysis of tumor-infiltrating leukocytes supported the conclusion that 5F8 exerts its effects on cytotoxic immune cell activation via LRP5 (Supplementary Fig. 9c,d) .
We also tested the importance of NK cell LRP5 in tumor progression and the antitumor effect of DKK2 blockade, using a mouse strain with NK-cell-specific LRP5 knockout (Lrp5 fl/fl Ncr1-Cre). MC38 tumors progressed more slowly in Lrp5 fl/fl Ncr1-Cre mice than in the control Lrp5 fl/fl mice, and 5F8 showed marginal antitumor effects in these mice (Supplementary Fig. 9e ). Concordantly, NK-cell-specific LRP5 knockout led to increased expression of NK cell activation markers, but had no effects on GZMB or CD69 in CD8 + T cells (Supplementary Fig. 9f,g ).
LRP5C interacts with and inhibits STAT5
To understand how LRP5 interferes with pSTAT5 nuclear localization, we carried out coimmunoprecipitation experiments, and found that LRP5 intracellular domain (LRP5C) interacted with STAT5 (Fig. 6d) . We next found that LRP5C inhibited IL-15-mediated activation of STAT5 reporter gene activity in HEK293 cells expressing JAK3, IL-2/IL-15β and common γ-receptor subunits (Fig. 6e) , without affecting STAT5 phosphorylation (Fig. 6f) . LRP5C also inhibited STAT5 reporter gene activity stimulated by a constitutively active JAK1 mutant (V658F) 41 expressed in HEK293 cells without altering STAT5 phosphorylation, but it did impair the nuclear localization of pSTAT5 (Fig. 6g,h ). These data are consistent with observations made in primary NK cells and support the conclusion that DKK2 inhibits IL-15 signaling by impeding the nuclear localization of pSTAT5, probably via LRP5C interaction with STAT5 as modeled in Supplementary Figure 9h Figure 4d , and then subjected to western blotting analysis (a) or immunostaining with anti-pSTAT5, anti-RAB8 (as a cytosol marker), and DAPI, followed by Alexa Fluor 647 and FITC-labeled secondary antibodies (b). Individual color channels are shown in Supplementary Figure 5f . Western blots for GZMB and perforin and the nuclear-to-cytosol (N/C) ratio of pSTAT5 staining were quantified (two-sided Student's t-test; n = 3 for western blotting; n = 15 for staining). Uncropped western blots are provided in Supplementary Figure 14 . internalization of LRP5 rather than LRP6 (Fig. 6i) provides a distinction between LRP5 and LRP6.
DKK2 suppresses tumor immune responses to anti-PD-1
We tested the combination of DKK2 blockade and PD-1 blockade in the MC38 tumor model. Although both PD-1 blockade and DKK2 blockade showed independent tumor-suppressive effects, the combination yielded further antitumor effects ( Supplementary  Fig. 10a,b) . Notably, a small fraction of tumors subjected to the combination treatment showed long-term regression ( Supplementary  Fig. 10a ). Flow analysis showed that individual blockades led to increased levels of GZMB in tumor-infiltrating CD8 + T cells and NK cells, and that the combination blockade resulted in further increases in GZMB expression in these cells (Supplementary Fig. 10c,d ).
We carried out intratumoral administration of recombinant DKK2 protein to directly assess the effect of DKK2 on tumor immune responses elicited by PD-1 blockade. DKK2 inhibited PD-1-blockadeinduced increases in the number of tumor-infiltrating CD45 + T cells and CD8 + T cells and the activation of CD8 + T cells and NK cells (Supplementary Fig. 10e ). These results suggest that DKK2 can suppress the effects of anti-PD-1 on immune effector cell activation. This conclusion is further supported by the observation that the effects of anti-PD-1 on tumor suppression and activation of tumor-infiltrated immune effector cells became insignificant in APC-null MC38-cellderived tumors (Supplementary Fig. 10f,g ), whereas DKK2 expression was upregulated (Supplementary Fig. 1e) . Analysis of the TCGA skin cutaneous melanoma cohort (provisional) revealed correlation of PTEN loss-of-function mutations and PI3K gain-of-function mutations with elevated DKK2 expression (Supplementary Fig. 11a ). These mutations lead to increased phosphatidylinositol-(3,4,5)-trisphosphate (PIP3) content in cells. In addition, a trend of correlation of PD-1 resistance with increased DKK2 expression (Supplementary Fig. 11b ) 42 and significant correlation with PTEN-loss mutations 43 has been observed in human melanomas. We thus tested the antitumor effect of DKK2 blockade by using YUMM1.7 mouse melanoma cells. The YUMM1.7 cells were derived from Braf V600E Pten −/− Cdkn2a −/− melanoma developed in C57BL/6 mice 44 . The Dkk2 mRNA content in YUMM1.7 cells, which was more than tenfold higher than that in MC38 cells, was reduced by the PI3K inhibitor wortmannin (Supplementary Fig. 11c ), which suggests that DKK2 expression is regulated by PIP3. We observed that 5F8 impeded tumor progression and extended the survival of tumor-bearing mice in the YUMM1.7 tumor model ( Supplementary  Fig. 11d,e) . Additionally, combined blockade of DKK2 and PD-1 outperformed blockade of only one or the other protein, with a fraction of combination-treated mice showing stable disease ( Supplementary  Fig. 11d,e) . Flow analysis of tumor-infiltrating leukocytes showed notably stronger activation of CD8 + T cells and NK cells by the combination blockade than by either individual blockade ( Supplementary  Fig. 11f ). These data support the conclusion alluded to earlier that DKK2 can suppress antitumor immune responses elicited by PD-1 blockade.
Applicability of DKK2 blockade for treatment of other cancers
Activated KRAS mutations frequently occur in advanced human cancers. We tested DKK2 blockade in a mouse lung cancer model carrying an activating Kras mutation. The model was generated by intranasal administration of Cre-expressing adenovirus to Apc fl/fl Kras act/+ mice. Treatment of these mice with 5F8 significantly reduced tumor burden (Supplementary Fig. 12a ) and increased the numbers and activation of CD8 + T cells and NK cells (Supplementary Fig. 12b-e) . These results, together with the correlation of high DKK2 expression with poor survival rates and of low GZMB expression with renal papillary carcinoma and bladder urothelial carcinoma revealed by the TCGA provisional database analysis (Supplementary Fig. 13a ), suggest that DKK2 blockade may also be applicable to the treatment of cancers other than CRCs. Given that DKK2 is generally expressed at low levels in various normal human and mouse tissues, particularly immune tissues (http://www.ebi.ac.uk/gxa/home), DKK2 blockade is not likely to be a strong risk factor for autoimmunity. Indeed, neither DKK2 deficiency nor LRP5 deficiency altered various hematopoietic cell populations or NK cell development in mice housed under specificpathogen-free conditions ( Supplementary Fig. 13b-e) . On the other hand, DKK2 may exert more potent effects on NK cells in tumors than those observed in our in vitro assays, as LRP5 expression was upregulated in tumor-infiltrating NK cells compared with that in primary NK cells from spleens ( Supplementary Fig. 13f ).
DISCUSSION
In this study, we uncovered a function of DKK2 in promoting tumor progression by suppressing NK cell and CD8 + T cell activation in an LRP5-dependent manner. It remains unclear why LRP6 is not required for this DKK2 action. The ability of DKK2 to induce internalization of only LRP5 (Fig. 6i) may provide an explanation. DKK1 and WNT3A also fail to induce internalization of endogenous LRP6 (refs. 45, 46) . The three putative adaptor-protein-2-binding motifs in LRP5, in contrast to just one in LRP6, may underlie the difference in their internalization 46 .
NK-cell-expressed STAT5 has direct roles in tumor immune surveillance 47 . On the basis of NK-cell-specific LRP5-knockout results, we believe that the DKK2-mediated impediment of STAT5 nuclear localization observed in this study is the primary mechanism for DKK2-mediated suppression of tumor immunity. DKK2 exerted a clear effect on STAT5 nuclear localization, but the effect was only partial (Fig. 5b) . This partial effect may explain why DKK2 affects only NK cell activation, and not NK cell development, which in turn explains the lack of effect of DKK2 inhibition on NK cell numbers in mice, even though deficiency of STAT5 or IL-15Rα has a profound effect on NK cell development [48] [49] [50] . Thus, NK cell development and full activation may have different thresholds for STAT5 signaling.
DKK2 can also inhibit IL-15-mediated activation of CD8 + T cells (Supplementary Fig. 6d ), presumably through a similar mechanism. Of note, LRP5 expression is upregulated in human mature CD8 + T cells 51 , which suggests that DKK2 may also exert a stronger effect on CD8 + T cells in vivo. However, DKK2 did not inhibit T-cellreceptor-mediated activation of primary T cells (data not shown). This explains the lack of an effect of DKK2 blockade on T cell populations. The activation of CD8 + T cells by DKK2 blockade could also be a result of a combination of DKK2's direct and NK-cell-mediated indirect regulation of CD8 + T cells 6, 52, 53 . Consistent with the prominent role of IL-15-STAT5 signaling in CD8 + intraepithelial cells [11] [12] [13] , DKK2 was able to inhibit CD8 + IELs isolated from mouse intestines (Supplementary Fig. 6e) . The direct inhibition of IELs by DKK2 may have a larger role in DKK2-blockade-associated increases in numbers of GZMB + CD8 + cells and tumor suppression in the Apc Min/+ intestinal tumor model, which is consistent with the CD8 + T cell depletion results (Supplementary Fig. 5d) . Therefore, the potent antitumor effects of DKK2 blockade in vivo may be the results of its direct effects on NK cells and/or CD8 + T cells, but the relative contributions of these mechanisms may be context dependent.
This study shows that APC loss drives DKK2 expression in CRCs, whereas PIP3-elevation mutations drive it in melanomas. We also found evidence that DKK2 provides resistance to PD-1 blockade in mouse models. These results suggest that DKK2 blockade may be used alone or in combination therapies to treat CRCs-the MSS CRCs in particular-and melanomas harboring PIP3-elevation mutations. DKK2 blockade may also be applied for the treatment of other human cancers in which DKK2 is expressed at high levels. These possibilities and the therapeutic potential of LRP5 blockade warrant future investigations.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
ONLINE METHODS
Mice. Dkk2 −/− mice were described previously 28, 30 and were back-crossed to the C57BL background for more than seven generations. Ncr1-Cre mice were also described previously 50 . NSG (NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ), Apc Min/+ (C57BL/6J-ApcMin/J), MX1 Cre (B6.Cg-Tg(Mx1-cre)1Cgn/J), Kras LSL-G12D (B6.129S4-Krastm4Tyj/J), and Apc fl/fl (C57BL/6-Apctm1Tyj/J) mice were acquired from the Jackson Laboratory. Wild-type C57BL/6 mice were purchased from Envigo (Harlan). The LoxP-floxed Lrp5 (Lrp5 fl/fl ) and Lrp6 (Lrp6 fl/fl ) mice were obtained from Bart Williams 54 . The Lrp5 fl/fl and Lrp6 fl/fl mice were back-crossed with C57BL/6 mice for more than seven generations before being intercrossed with MX1 Cre mice. Lrp5 and Lrp6 gene disruption was induced by intraperitoneal injection of 40 µl of poly-I:C (10 mg/mL) into the Lrp5 fl/fl MX1 Cre mice every other day for four treatments. The mice were used for NK cell isolation 3 weeks after the poly-I:C treatment. For adoptive bone marrow transfer, bone marrow from Lrp5 fl/fl MX1 Cre mice was transferred into lethally irradiated C57BL/6 mice (8-week-old females) via retro-orbital injection. After recovery (8 weeks), the mice were treated with poly-I:C and used in experiments 3 weeks after poly-I:C treatment. Mice were housed in specific-pathogen-free conditions and cared for in accordance with US National Institutes of Health guidelines, and all procedures were approved by the Yale University Animal Care and Use Committee. . Mouse monoclonal antibody (mAb) to DKK2 (5F8) was generated by standard hybridoma technology through immunization of mice with a synthetic peptide (KLNSIKSSLGGETPGC) of human DKK2 at AbMax (Beijing, China). Therapeutic antibodies to PD-1 were hamster mAb clone G4 (ref. 55) and Clone J43 (BioXcell, BP0033-2) with polyclonal Armenian hamster IgG (BioXcell, BE0091) as the control IgG.
HEK293 and HCT-116 cells were purchased from ATCC. YUMM1.7 was provided by M.B. and was reported previously 44 . MC38 was purchased from Kerafast (Boston, MA). Cells were all tested for mycoplasma and were shown to be negative. ELISA. Recombinant mouse DKK2 or DKK1 protein (20 ng/ml; R&D) in a blocking buffer (1% BSA in PBS) was incubated in a 384-well microtiter plate overnight at 4 °C. The plate was washed with PBS twice and incubated with the blocking buffer for 1 h at room temperature. The plate was then incubated with the 5F8 antibody in the blocking buffer for 1 h at room temperature. After repeated washing, the plate was incubated with an HRP-conjugated secondary antibody for 1 h at room temperature. A chemiluminescent substrate (Thermo Fisher, 37070) was added to the plate, and the plate was read by an EnVision plate reader. DKK2-AP binding assay. The binding assay was performed as previously described 60 . In brief, HEK293 cells were transfected with LacZ or LRP5 using Lipofectamine Plus for 24 h. Cells were washed once with a cold washing buffer (Hanks' buffered salt solution containing 1% bovine serum albumin, 20 mM HEPES, and 0.5% NaN 3 ) and incubated with washing buffer containing 20% DKK2-AP conditioned medium on ice for 2 h. The cells were then washed three times with the washing buffer and lysed with 1% Triton X-100 and 20 mM TrisHCl, pH 7.5. The lysates were heated at 65 °C for 10 min to inactivate endogenous AP and then added with a chemiluminescence AP substrate (Thermo Fisher, T1015). The activity was measured by an EnVision plate reader.
Tumor graft. MC38 or YUMM1.7 melanoma tumor cells (0.5-1 × 10 6 ) were mixed with BD Matrigel (Matrix Growth Factor Reduced) (BD, 354230) in 100 µl and injected subcutaneously into the right flanks of the backs of female C57BL mice (8-10 weeks old). Tumor growth was measured with calipers, and size was expressed as one-half of the product of perpendicular length and square width in cubic millimeters. For antibody treatment, control IgG3 antibody and anti-DKK2 were diluted in PBS, and 100 µl was injected intraperitoneally (i.p.) at the intervals indicated in the figures. For survival tests, mice were euthanized when the tumor size exceeded 1,500 mm 3 for MC38 and 1,200 mm 3 for YUMM1.7.
Preparation of tumor-infiltrating leukocytes. Tumors were minced with scissors and scalpel blades and incubated with digestion buffer (RPMI 1640 medium, 5% FBS, 1% penicillin-streptomycin, 25 mM HEPES, and 300 U collagenase (Sigma C0130)) in a shaker for 2 h at 37 °C. Disperse cells were filtered through a 70-µm cell strainer to eliminate clumps and debris. After centrifugation for 5 min (500g) at 4 °C, cell pellets were resuspended in red blood cell lysis buffer (Sigma R7757) and incubated at room temperature for 5 min to remove erythrocytes. Cells were pelleted again, resuspended, and incubated in 0.05% Trypsin/EDTA at 37 °C for 5 min, after which they underwent DNA digestion with the addition of type I DNase (1 µg/ml final; Sigma, D4263) for 5 min. Trypsin digestion was stopped by the addition of FBS to 5%, and cells were filtered again through a 40-µm cell strainer. Finally, the cells were pelleted again and resuspended in PBS at a concentration of 2 × 10 7 .
Flow cytometry. Cells in single-cell suspension were fixed with 2% PFA (Santa Cruz, sc-281692). After being washed with a flow cytometry staining buffer (eBioscience, 00-4222-26), cells were stained with antibodies for cell-surface markers for 1 h on ice in the dark. For staining of intracellular proteins, the cells were washed and resuspended in permeabilization buffer (BD, 554723) and stained by antibodies in the permeabilization buffer for 1 h on ice in the dark. The cells were then pelleted and resuspended in the flow cytometry staining buffer for flow cytometry analysis.
Tumor sectioning and immunostaining. Tissues were fixed with 4% PFA (Santa Cruz, sc-281692) for 4-6 h on a shaker at 4 °C. They were then washed with PBS three times and perfused in 20% sucrose solution in PBS overnight at 4 °C. They were subsequently mounted in OCT embedding compound and frozen first at -20 °C and then at -80 °C. Tissue sections were prepared at 8-µm thickness with a cryostat and mounted onto gelatin-coated histological slides, which were stored at -80 °C.
For immunostaining, slides were thawed to room temperature and fixed in pre-cold acetone for 10 min, then rehydrated in PBS for 10 min. The slides were incubated in a blocking buffer (1% horse serum and 0.02% Tween 20 in PBS) for 1-2 h at room temperature, then incubated with primary antibodies, which were diluted in the blocking buffer, overnight at 4 °C. The slides were then washed three times with PBS and incubated with a secondary antibody (donkey nature medicine doi:10.1038/nm.4496
anti-rabbit IgG H&L (DyLight 550) preadsorbed (Abcam, ab96920)) in the incubation buffer for 1 h at room temperature. After repeated washes, the slides were mounted with an anti-fade mounting media containing DAPI (Thermo Fisher, P36931) and visualized with a confocal microscope.
Cytotoxic effector immune cell depletion. For depletion of NK cells with the MC38 model, anti-NK1.1 (PK136, BioXcell BE0036) or isotype control antibody (BioXcell BE0085) was injected i.p. at 300 µg per mouse on days -1, 5, 11 and 17 relative to tumor cell inoculation. For CD8 depletion, anti-CD8α (YTS169.4, BioXcell BE0117) or isotype control antibody (Clone LTF-2, BioXcell BE0090) was injected i.p. at 300 µg per mouse at days 12, 15, and 19 after tumor cell inoculation.
For the Apc Min/+ model, NK1.1 + and CD8 + T cells were depleted by i.p. injection of 10 mg/kg anti-NK1.1 (PK136, BioXcell BE0036) and anti-CD8α (YTS169.4, BioXcell BE0117), respectively. Male Apc Min/+ mice were treated weekly with the control IgG3 antibody or 5F8 (8 mg/kg) starting at the age of 15 weeks. The depletion antibodies were given 6 d before the therapeutic treatment at an interval of 5 d. The mice were examined 4 weeks after the treatment.
Preparation and treatment of mouse primary NK cells, CD8 + T cells and IELs.
Mouse primary NK cells and CD8 + T cells were isolated from the spleens of female mice (8 weeks old) with NK cell and CD8 + T cell isolation kits according to the manufacturer's instructions (Miltenyi Biotec #130-090-864 and #130-104-075, respectively). Primary NK cells were cultured in RPMI 1640 medium (Gibco, 11875-093) supplemented with 10% FBS, penicillin (100 U/ml), streptomycin (100 µg/ml), 2-mercaptoethanol (500 µM), and HEPES (10 mM) at 37 °C supplemented with 5% CO 2 in the presence of recombinant murine IL-15 (50 ng/ml) for 24 h before treatment with DKK2, CHIR99021, or WNT3A. CD8 + T cells were cultured in the same culture medium and conditions as NK cells, but were supplemented with IL-15 (200 ng/ml) and IL-15Rα (1 µg/ml recombinant mouse IL-15 receptor-α Fc chimera protein from R&D) for 96 h before DKK2 treatment.
Mouse primary IELs were prepared as described in refs. 61,62. In brief, the small intestine was everted, divided into four pieces, and washed twice in PBS containing 100 U/ml penicillin-streptomycin. The specimens were then incubated with stirring at 37 °C in prewarmed Ca 2+ -and Mg 2+ -free Hanks' solution containing 100 U/ml penicillin-streptomycin, 5% FCS, 2 mM dithiothreitol, and 5 mM EDTA for 30 min, and then shaken vigorously for 30 s. The supernatants were passed over two nylon wool columns to remove undigested tissue debris. The lymphocytes obtained were pooled and enriched on a discontinuous (40% and 70%) Percoll density gradient. Cells at the interface between the 40% and 70% fractions (IELs) were collected for treatment with IL-15 (200 ng/ml) and DKK2 (400 ng/ml), and then subjected to flow analysis.
Preparation of human NK cells.
Peripheral blood mononuclear cells from healthy humans were purchased from ZenBio (SER-PBMC-200). Human NK cells were isolated from the PBMCs with a human NK cell isolation kit according to the manufacturer's instruction (Miltenyi Biotec, #130-092-657). Human NK cells were cultured in RPMI 1640 medium (Gibco, 11875-093) supplemented with 10% heat-inactivated FBS, penicillin (100 U/ml), streptomycin (100 µg/ml), 2-mercaptoethanol (500 µM), and HEPES (10 mM) at 37 °C, supplemented with 5% CO 2 , in the presence of recombinant human IL-15 (50 ng/ml) before treatment with recombinant human DKK2 protein.
NK cell and tumor cell coculture. Primary NK cells were isolated from spleens as described above and cultured in the presence of 50 ng/ml recombinant murine IL-15 for 24 h. Meanwhile, tumor cells were plated in a 96-well plate and left overnight. NK cells were added into the tumor cells at a 7:1 ratio in the presence of the IgG3 antibody or anti-mDKK2 5F8 for 9 h at 37 °C. To test the effect of DKK2 in coculture, we cultured isolated NK cells in the presence of 50 ng/ml recombinant murine IL-15 for 24 h and then in the presence or absence of DKK2 for another 24 h before adding the NK cells to pre-seeded MC38 cells at a 7:1 (NK:MC38) ratio. The numbers of live tumor cells were determined by a Guava flow cytometer (EMD Millipore), whereas the cell apoptosis was assessed by flow cytometry with an annexin V apoptosis detection kit (eBioscience, 88-8007).
Immunocytostaining. Primary NK cells were prepared as described above and treated as indicated in the figures. They were then placed on poly-lysine-coated coverslips and incubated for 30 min at room temperature. HEK293 cells grown on coverslips were transfected and stimulated as indicated in the figures. Cells were fixed with 4% PFA for 10 min at room temperature and permeabilized with ice-cold methanol for 10 min at -20 °C. After being rinsed with PBS three times, cells were blocked with a blocking buffer (5% normal donkey serum and 0.5% Triton in PBS) for 1 h at room temperature. Primary antibodies were then diluted in PBS with 0.5% BSA and applied to cells for overnight incubation at 4 °C. Cells were rinsed with PBS three times and incubated with diluted fluorochrome-conjugated secondary antibodies (in PBS with 1% BSA) for 1 h at room temperature. Finally, cells were rinsed with PBS three times and mounted with Prolong Gold Antifade solution (Thermo Fisher) for confocal microscopy.
For quantification of subcellular localization, we determined the nuclear/ cytoplasmic ratio of pSTAT5 staining intensities. The staining intensities of pSTAT5 in the nuclei, which were delineated by DAPI staining, and in the cytosol, which was delineated by RAB8 staining, were quantified in ImageJ.
Immunoprecipitation. 293T cells were transfected with plasmids encoding STAT5 and/or LRP5C-Flag with Lipofectamine Plus. The cells were lysed 24 h after transfection in lysis buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 1% Triton X-100, 10% glycerol, 2 mM MgCl 2 , 2 mM EGTA) with protease inhibitor cocktail (Roche) and phosphatase inhibitors (Phospo-stop; Roche) on ice. Cell lysates were centrifuged to remove insoluble materials. Immunoprecipitation was performed with anti-Flag overnight, and was followed by 2-h incubation with Protein-A/G Plus beads (Santa Cruz) at 4 °C. The beads were washed repeatedly, and bound proteins were analyzed by western blotting. The Wnt reporter gene assay was carried out in HEK293 cells that were transfected with TOPFlash and GFP plasmids. The rest of the protocol was the same as described above. The reporter gene activity presented is normalized against GFP readings.
Generation of APC-mutant cells. Gene editing of the APC genes in MC38 and HCT116 cells was done via the CRISPR-Cas9 system as previously described 63 . The cells were transfected with two Cas9 plasmids expressing two guiding RNAs targeted to the gene encoding APC. This caused homozygous C-terminal deletion of the APC protein starting at Gly855 in MC38 cells. As these two guiding RNAs were coexpressed with GFP or RFP, respectively, the GFP + RFP + cells were sorted directly into 96-well plates at a density of 1.2 cells per well. Homozygous mutations in APC or Apc were detected by PCR and confirmed by DNA sequencing. Positive clones were pooled to avoid clonal effects. The guiding and PCR sequences are listed in Supplementary Table 2. LRP5/6 internalization assay. HEK293 cells were treated with mock or recombinant mouse DKK2 protein (250 ng/ml) in culture medium for the durations indicated in the figures. The cells were washed with pre-cold PBS, and cell-surface proteins were biotinylated with 0.5 mg/ml EZ-Link Sulfo-NHS-SS-Biotin (Thermo Fisher, 21445) in a PBS buffer on ice for 30 min. The reaction was stopped by the addition of PBS containing ice-cold 50 mM NH 4 Cl, followed by repeated washes with ice-cold PBS. The cells were then lysed in a buffer containing 1.25% Triton X-100, 0.25% SDS, 50 mM Tris-HCl, pH 8.0, 150 mM NaCl,nature medicine doi:10.1038/nm.4496 and the rest of supernatants were used in pulldowns with NeutrAvidin beads (Thermo Fisher, 29200) followed by western blotting analysis.
Cell fractionation. Cell fractionation was carried out with the cell fractionation kit from Cell Signaling Technology (#9038) according to the manufacturer's protocol. In brief, primary NK cells (2 million) were washed with cold PBS and resuspended in cytoplasm isolation buffer. After centrifugation, the supernatant was collected as the cytosol fraction and the pellet was resuspended in membrane isolation buffer. After centrifugation, the supernatant was collected with the membrane fraction, whereas the pellet was collected as the nuclear fraction. The nuclear fraction and the pool of the membrane and cytosolic fractions were subjected to western blotting analysis.
RNA sequencing and data analysis. Primary NK cells were isolated from spleens as described above and cultured in the presence of 50 ng/ml recombinant murine IL-15 for 24 h and then cultured in the presence or absence of 500 ng/ml DKK2 for another 24 h before mRNA was isolated and purified with the RNeasy Plus mini kit (Qiagen). RNA-seq libraries were prepared with the TrueSeq stranded total RNA library prep kit (Illumina) and sequenced on an Illumina HiSeq 2500 with 50-base single-end reads.
Raw sequence reads were mapped with TopHat in Galaxy (Version 2.1.0) with ENCODE annotation M1. The raw counts were then normalized via the trimmed mean of M values (TMM) method and compared using the Bioconductor package edgeR. Reads per kilobase per million mapped reads (RPKM) were also calculated from the raw counts and have been deposited at GEO (GSE100402). Differentially expressed genes were identified if RPKM ≥ 1 in at least one sample, and fold change was ≥1.25. Pathway analysis of RNA-sequencing results was performed with Enrichr (http://amp.pharm.mssm.edu/Enrichr). Gene enrichment analysis was performed with Motif Gene Set (http://software.broadinstitute. org/gsea/msigdb/index.jsp) 64 .
In situ hybridization. In situ hybridization detection of Dkk2 mRNA was carried out with the following reagents acquired from Advanced Cell Diagnostics, using the provided protocol: RNAscope Target Retrieval Reagents (322000), RNAscope Pretreat Reagents-H202 and ProteasePlus (322330), RNAscope 2.5 HD Detection Reagent-RED (322360), RNAscope Wash Buffer Reagents (310091), BioCare EcoMount (320409), ImmECatdge Hydrophobic Barrier Pen (310018), and the mouse Dkk2 probe (404841).
Correlation of DKK2 expression and survival. Data on DKK2 expression, overall survival, and relapse-free survival were obtained from the TCGA provisional data sets as of 20 July 2016. The high and low DKK2 expressers were grouped on the basis of an arbitrary cutoff percentile of 15%. Mantel-Cox log-rank tests were done using the GraphPad Prism 7 software.
Statistical analysis and study design. Minimal group sizes for tumorprogression studies were determined via power calculations with the DSS Researcher's Tookit with an α of 0.05 and power of 0.8. Animals were grouped unblinded, but randomized, and investigators were blinded for the qualification experiments. No samples or animals were excluded from analysis. Assumptions concerning the data including normal distribution and similar variation between experimental groups were examined for appropriateness before statistical tests were conducted. Comparisons between two groups were performed by unpaired, two tailed t-test. Comparisons between more than two groups were performed by one-way ANOVA, whereas comparisons with two or more independent variable factors were performed by two-way ANOVA followed by Bonferroni's post hoc correction using Prism 6.0 software (GraphPad). Statistical tests were done with biological replicates. P < 0.05 was considered statistically significant.
Life Sciences Reporting Summary. Further information on experimental design and reagents is available in the Life Sciences Reporting Summary.
Data availability. The raw RNA-seq data are available in the NCBI Gene Expression Omnibus (GSE100402).
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Experimental design 1. Sample size
Describe how sample size was determined.
Minimal group sizes for tumor progression studies were determined by using power calculations with the DSS Researcher's Tookit with an α of 0.05 and power of 0.8.
Data exclusions
Describe any data exclusions.
No data were excluded from analysis.
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
All attempts at replication were successful.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
All mice were randomly assigned to experimental groups.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Animals were grouped unblinded, but investigators were blinded for most of the qualification experiments.
Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)
See the web collection on statistics for biologists for further resources and guidance.
